Your Health, We Care
The most common (≥ 20%) adverse reactions are:
1.As a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, constipation.
2.In combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.
from FDA，2023.09
Cabozantinib is a widely used drug for the treatment of a variety of cancers, an···【more】
Release date：2025-02-21Recommended：82
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has demonstrated···【more】
Release date：2025-02-21Recommended：109
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has shown signif···【more】
Release date：2025-02-20Recommended：90
